Ads
related to: clinical trials for hodgkin's lymphoma disease- What to Expect
Learn More About What to Expect
From a Hodgkin Lymphoma Treatment.
- Pediatric Treatment
Learn More About a Hodgkin Lymphoma
Treatment Option for Your Child.
- Study Results
Visit the Site to Access Clinical
Study Results & Side Effects Info.
- Support & Resources
Explore Support & Resource Info
on a Hodgkin's Treatment Option.
- What to Expect
Search results
Results from the WOW.Com Content Network
Stanford V (usually spoken as Stanford Five), is a chemotherapy regimen (with accompanying Radiation therapy) intended as a first-line treatment for Hodgkin lymphoma.The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens ...
Currently, more than 20 clinical trials are ongoing to evaluate the anti-tumor effect of sintilimab injection, either as monotherapy or in combination with other agents, on a variety of solid tumors. [10] In January 2019, the result of the registration trial of sintilimab in people with refractory or relapsed classical Hodgkin's lymphoma was ...
Hodgkin's lymphoma, Hodgkin's disease [1] Micrograph showing ... Clinical research strategies are exploring reduction of the duration of chemotherapy and dose and ...
A number of trials then compared MOPP vs. MOPP plus ABVD [17] and compared ABVD to previous and other regimens for Hodgkin lymphoma. A large trial by CALGB suggested that ABVD was superior to MOPP, with a higher rate of overall response, less hematologic toxicity, better relapse-free survival, and better outcomes after relapse in the patients ...
AOH1996 is an experimental anticancer medication which acts as a small molecule inhibitor of proliferating cell nuclear antigen (PCNA) and is in Phase I clinical trials at City of Hope as of August 2023 for the treatment of solid tumors. [1] [2] [3] [4]
BEACOPP is a chemotherapy regimen for treatment of Hodgkin lymphoma developed by the German Hodgkin Study Group [1] used for patients in Stages > II or early (IA or IB) with unfavorable risk factors. [2] Patients typically receive treatment in cycles of 21 days with no drugs given on days 15–21. [3]
The Leukemia & Lymphoma Society (LLS), a 501(c)(3) charitable organization founded in 1949, is a voluntary health organization dedicated to fighting blood cancer world-wide. LLS funds blood cancer research on cures for leukemia, lymphoma, Hodgkin's disease, and myeloma. It provides free information and support services, and it advocates for ...
As of August 2012, it is being tested against Hodgkin's Lymphoma, cutaneous T cell lymphoma (CTCL) [13] and other types of malignant disease in Phase III clinical trials, against myelodysplastic syndromes, breast cancer and prostate cancer in Phase II trials, and against chronic myelomonocytic leukemia (CMML) in a Phase I trial.
Ads
related to: clinical trials for hodgkin's lymphoma disease